Needham & Company LLC Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs (NASDAQ:ESTA) had its target price lifted by Needham & Company LLC from $48.00 to $70.00 in a research report issued to clients and investors on Thursday, Marketbeat reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 7.69% from the company’s previous close.

Other analysts have also issued research reports about the stock. Mizuho upped their target price on shares of Establishment Labs from $70.00 to $85.00 and gave the stock an “outperform” rating in a report on Thursday. Citigroup restated a “neutral” rating on shares of Establishment Labs in a research report on Tuesday, October 7th. BTIG Research raised their price target on Establishment Labs from $62.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Establishment Labs in a research report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and an average price target of $66.71.

Establishment Labs Stock Up 0.1%

Shares of ESTA traded up $0.09 on Thursday, reaching $65.00. The company’s stock had a trading volume of 1,048,731 shares, compared to its average volume of 571,818. The stock has a market capitalization of $1.88 billion, a PE ratio of -22.89 and a beta of 0.98. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71. Establishment Labs has a twelve month low of $26.56 and a twelve month high of $65.45. The firm has a fifty day moving average of $44.13 and a 200-day moving average of $40.41.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.16. The company had revenue of $53.78 million during the quarter, compared to the consensus estimate of $52.28 million. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 201.85%. The firm’s revenue for the quarter was up 33.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.59) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. Equities analysts predict that Establishment Labs will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. New York State Common Retirement Fund purchased a new stake in shares of Establishment Labs during the first quarter worth about $894,000. Rice Hall James & Associates LLC increased its stake in Establishment Labs by 7.4% in the 1st quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company’s stock worth $33,763,000 after acquiring an additional 56,756 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new position in shares of Establishment Labs during the 1st quarter valued at approximately $81,000. Royce & Associates LP grew its holdings in shares of Establishment Labs by 82.4% in the first quarter. Royce & Associates LP now owns 192,491 shares of the company’s stock valued at $7,855,000 after purchasing an additional 86,965 shares in the last quarter. Finally, Federated Hermes Inc. increased its position in Establishment Labs by 28.2% in the first quarter. Federated Hermes Inc. now owns 41,937 shares of the company’s stock worth $1,711,000 after purchasing an additional 9,217 shares during the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.